Logo image of OGEN

ORAGENICS INC (OGEN) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:OGEN - US6840236094 - Common Stock

0.8216 USD
-0.04 (-4.35%)
Last: 12/29/2025, 7:10:47 PM
0.8113 USD
-0.01 (-1.25%)
After Hours: 12/29/2025, 7:10:47 PM
Fundamental Rating

0

OGEN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of OGEN have multiple concerns. OGEN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OGEN had negative earnings in the past year.
OGEN had a negative operating cash flow in the past year.
In the past 5 years OGEN always reported negative net income.
In the past 5 years OGEN always reported negative operating cash flow.
OGEN Yearly Net Income VS EBIT VS OCF VS FCFOGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

OGEN has a worse Return On Assets (-717.68%) than 97.17% of its industry peers.
Industry RankSector Rank
ROA -717.68%
ROE N/A
ROIC N/A
ROA(3y)-410.14%
ROA(5y)-285.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OGEN Yearly ROA, ROE, ROICOGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K -6K

1.3 Margins

OGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGEN Yearly Profit, Operating, Gross MarginsOGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

0

2. Health

2.1 Basic Checks

OGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
OGEN has more shares outstanding than it did 1 year ago.
OGEN has more shares outstanding than it did 5 years ago.
OGEN has a worse debt/assets ratio than last year.
OGEN Yearly Shares OutstandingOGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
OGEN Yearly Total Debt VS Total AssetsOGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

OGEN has an Altman-Z score of -228.67. This is a bad value and indicates that OGEN is not financially healthy and even has some risk of bankruptcy.
OGEN's Altman-Z score of -228.67 is on the low side compared to the rest of the industry. OGEN is outperformed by 97.17% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -228.67
ROIC/WACCN/A
WACC8.25%
OGEN Yearly LT Debt VS Equity VS FCFOGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 0.87 indicates that OGEN may have some problems paying its short term obligations.
OGEN has a worse Current ratio (0.87) than 89.06% of its industry peers.
OGEN has a Quick Ratio of 0.87. This is a bad value and indicates that OGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
OGEN has a Quick ratio of 0.87. This is amonst the worse of the industry: OGEN underperforms 88.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
OGEN Yearly Current Assets VS Current LiabilitesOGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.49% over the past year.
The Revenue for OGEN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)78.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.02% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.67%
EPS Next 2Y40.35%
EPS Next 3Y25.6%
EPS Next 5Y15.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OGEN Yearly Revenue VS EstimatesOGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2021 2022 2023 200K 400K 600K 800K
OGEN Yearly EPS VS EstimatesOGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -200 -400 -600 -800 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OGEN. In the last year negative earnings were reported.
Also next year OGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OGEN Price Earnings VS Forward Price EarningsOGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGEN Per share dataOGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30 -40 -50

4.3 Compensation for Growth

A more expensive valuation may be justified as OGEN's earnings are expected to grow with 25.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.35%
EPS Next 3Y25.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ORAGENICS INC

NYSEARCA:OGEN (12/29/2025, 7:10:47 PM)

After market: 0.8113 -0.01 (-1.25%)

0.8216

-0.04 (-4.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07
Earnings (Next)03-12 2026-03-12/amc
Inst Owners4.69%
Inst Owner Change83.48%
Ins Owners0.41%
Ins Owner Change-0.03%
Market Cap3.43M
Revenue(TTM)N/A
Net Income(TTM)-10.57M
Analysts82.86
Price Target2.04 (148.3%)
Short Float %0.85%
Short Ratio0.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-56.05
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -717.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-410.14%
ROA(5y)-285.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z -228.67
F-Score2
WACC8.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.29%
EPS Next Y96.67%
EPS Next 2Y40.35%
EPS Next 3Y25.6%
EPS Next 5Y15.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y49.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.76%
EBIT Next 3Y-28.26%
EBIT Next 5YN/A
FCF growth 1Y-3.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.92%
OCF growth 3YN/A
OCF growth 5YN/A

ORAGENICS INC / OGEN FAQ

What is the ChartMill fundamental rating of ORAGENICS INC (OGEN) stock?

ChartMill assigns a fundamental rating of 0 / 10 to OGEN.


What is the valuation status for OGEN stock?

ChartMill assigns a valuation rating of 1 / 10 to ORAGENICS INC (OGEN). This can be considered as Overvalued.


What is the profitability of OGEN stock?

ORAGENICS INC (OGEN) has a profitability rating of 0 / 10.